Although DOT has also historically been administered by credentialed health professionals, this strategy is often cost-prohibitive for many health systems. Our findings imply that DOT can be effectively implemented by CHWs in the USA and may be an economically feasible alternative. As growing evidence links this model to improved clinical outcomes in

HIV infection and other chronic conditions, a comparison between the cost-effectiveness of the CHW model and that of the DOT model in the USA would be a worthwhile focus for future research endeavours. Despite the promise of the CHW model, few studies have described TSA HDAC concentration CHW interventions addressing HAART adherence in the USA, and even fewer have reported the results Roxadustat clinical trial of randomized controlled trials. Our literature search yielded many articles that provided important information about the effects

of the CHW model on HAART adherence but were excluded from this review because they were not conducted in the USA or did not report biological HIV outcomes. As a result, only 16 studies met our inclusion criteria. This reflects the general paucity of CHW programmes in the USA. In addition, compared with CHW programmes in international communities, studies in the USA generally included fewer participants. The resulting limited number of participants in US studies, and specifically in those included in our review, makes it difficult to generalize these results to the larger general population of the USA. Yet another aspect of these studies that limits the generalizability

of the findings is that the populations studied were highly specific, small groups of patients (e.g. substance abusers), with differences among the studies in the demographic characteristics of the patient groups (e.g. in geographical origin, age and ethnicity). Because of the relatively low numbers of subjects and published studies, it was not possible to compare only studies that were homogeneous Bortezomib manufacturer in terms of these variables. This highlights the need for future multisite studies with consistent methodologies to determine how geographical and population differences influence outcomes. While all of the studies included in this review used biological markers as outcome measurements, the characteristics of the interventions varied, and each study utilized CHWs in unique ways. However, because of the relative dearth of studies in the USA on this subject, it was not possible to find an adequate number of studies with identical interventions to compare. It is therefore difficult to determine which specific CHW activities are most effective at improving adherence. Multiple studies with identical use of CHWs must be carried out in the future to further assess which CHW strategies are most efficacious. Another limitation of our review is that many of the articles provided limited details about the specific CHW services.